Andrew Geall | Chief Development Officer
Replicate Bioscience, Inc.

Andrew Geall, Chief Development Officer, Replicate Bioscience, Inc.

Dr. Andrew Geall is the Chief Development Officer at Replicate Bioscience and co-founder of the company. Dr. Geall has over 20 years of professional experience in the development of drug delivery systems and is a pioneer in the fields of mRNA vaccines and nucleic acid delivery. He is an inventor on 41 patent families, with 505 applications and 203 issued patents in multiple jurisdictions.

Prior to joining Replicate, Dr. Geall was Chief Scientific Officer at Precision NanoSystems Inc. (PNI). Here, he focused on the creation of transformative nanoparticle medicines using their proprietary LNP delivery systems and microfluidic formulation platform. He has also held positions as Vice President of Formulations, Analytics and Chemistry at Avidity Biosciences, where he pioneered the development of their antibody-oligonucleotide conjugate delivery platform. As a member of the Executive Management, he helped raise over $100 million in venture capital and took the company public in June 2020 with an initial public stock offering of $259 million.

Prior to Avidity, he led the development of the mRNA vaccines platform in the Vaccine division of Novartis. Over 7 years, he created a global team and was Principal Investigator on a Defense Advanced Research Project Agency (DARPA) contract to develop self-amplifying mRNA vaccines. Dr. Geall also had a two-year tenure at Novartis Pharmaceuticals AG, where he was the Global siRNA Formulation Team Leader, responsible for the design and implementation of the siRNA delivery strategy.
Dr. Geall received his pharmacy degree from the University of Bath in the UK and went on to do his pre-registration training, as a hospital Pharmacist, in the aseptic dispensing unit at St Helens and Knowsley Trust Hospitals. He then obtained his PhD at University of Bath in non-viral gene delivery.

Appearances:



Pre-Congress Workshops - Monday 1st April @ 10:00

RNA - From vaccines to therapeutics

How are we improving our understanding of RNA technology for next generation vaccines? How will RNA transform therapeutics and cancer treatment?

10:00 Chair opening remarks

Prof Jeffrey Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics Professor of Molecular Biology and Genetics, Johns Hopkins University

10:10 mRNA vaccines of the future: Bridging the Knowledge Gaps

Dr Sudha Chivukula, AVP, Head of Discovery Biology, mRNA Centre of Excellence, Sanofi

10:25 Beyond respiratory vaccines

Dr Jacqueline Miller, SVP, Therapeutic Area Head - Infectious Disease Development, Moderna

10:45 Individualized mRNA vaccines

Ruben Rizzi, Senior Vice President Global Regulatory Affairs, BioNtech

11:00 Accessing vast design space with modular high throughput platform for RNA therapeutics and vaccines

Dr Sarit Schwartz, Head of RNA, Business Development Gingko Bioworks

11:15 Analytical challenges in characterization of multivalent mRNA vaccines

Dr Gautam Sanyal, Principal Consultant and Founder, Vaccine Analytics, LLC

11:30 RNABL: A Novel RNA Delivery Platform for Therapeutic Applications

Dr Micheal Breen, Scientist, Tiba Biotech

11:45 From a preventive vaccine to a therapeutic vaccine

Dr Jason Zhang, CEO and Co-Founder, ZipCode Bio

12:00 – 1:00 Panel: Beyond prophylactic vaccines: the future of RNA therapeutics

  • What is the potential for RNA use in therapeutics?
  • Cancer, immunotherapy, gene editing etc.
  • What gaps remain to successfully utilize the potential of RNA beyond vaccines?

Moderator: Anna Rose Welch, Editorial and Community Director, Advancing RNA, Life Science Connect

Dr Gilles Besin, Chief Scientific Officer, Orbital Therapeutics

Dr Gopi Shanker, Chief Scientific Officer, Beam Therapeutics

Dr Andrew Geall, Chief Development Officer, Replicate Bioscience

Dr Kate Zhang, Chief Scientific Officer, Hopewell Therapeutics

last published: 28/Mar/24 22:05 GMT

back to speakers